Min.Order / FOB Price:Get Latest Price
10 Gram |
FOB Price:USD 1.0000 -2.0000 |
Oxaliplatin Oxaliplatin supplier 61825-94-3
1,Best Quality: Our products have exported to Germany, Spain, UK, USA, Australia, Middle East, and so on other countries, and we have got very good feedback from our customers.so you can trust us. 2, Payment method: for example T/T, Westerm Union,other 3, Excellent Service: Best service and after-sales service to all clients. 1)We will ship the goods within 5days after get your payments.If you want to cancel or change order, please tell me within 24hours after you finish the payment.. 2)We will ship the goods that you order from us by DHL, UPS, TNT and EUB.We will decided to choose which courier depend on different countries.To find the best way to delivery the goods for you. 3)As usual you can get the goods with in 4-7days.If the goods were lost or not received for other reasons, please contact us immediately. 4,Fast and safe delivery: Sample Order : As usual you can get the goods within 4-7days. We can send it via HKems, HK Air Post, DHL or other methods. We have a professional and stable logistics, and we can deliver the package smoothly around 3 to 5 days. Bulk Order: Shipped via sea or air, it's according to your requirement, delivery time is 7-15days after payment. We introduce experienced quality product and exceptional JIT service with instant market intelligence in China to benefit our customers and principals. With our high-performance teamwork centers and associated production sites for custom synthesis, we ensure effective professional response and offer extensive applications-related consulting and compliance regulation services. |
Oxaliplatin Basic information |
Product Name: | Oxaliplatin |
Synonyms: | [SP-4-2-(1R-TRANS)]-(1,2-CYCLOHEXANEDIAMINE-N,N')[ETHANEDIOATA(2-)-O,O']PLATINUM;OXALIPLATIN;trans-l-diaminocyclohexane oxalatoplatinum;(1,2-cyclohexanediamine-n,n’)(ethanedioato(2-)-o,o’)-platinu(sp-4-2-(1r-tr;1-ohp;oxalato(1r,2r-cyclohexanediammine)platinum(ii);oxalatoplatin;oxalatoplatinum |
CAS: | 61825-94-3 |
MF: | C8H14N2O4Pt |
MW: | 397.29 |
EINECS: | 274-613-9 |
Product Categories: | Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;APIs;Amines;Heterocycles;chemical reaction,pharm,electronic,materials;PRAXILENE;Inhibitors |
Oxaliplatin Chemical Properties |
storage temp. | Store at +4°C |
form | solid |
Stability: | Stable. Store cool. Incompatible with oxidizing agents. |
Safety Information |
Hazard Codes | Xn,Xi |
Risk Statements | 36/37/38-40-42/43 |
Safety Statements | 26-36 |
RIDADR | 2811 |
WGK Germany | 3 |
RTECS | TP2275850 |
HazardClass | 6.1(a) |
PackingGroup | II |
MSDS Information |
Provider | Language |
---|---|
SigmaAldrich | English |
Oxaliplatin Usage And Synthesis |
Treatment of colorectal cance |
Oxaliplatin belongs to platinum derivatives for the treatment of patients with colorectal cancer metastasis after the failure of the clinical treatment through fluorouracil , it can be used alone or in combination with the use of fluorouracil, it is the third generation of new class of anti-tumor platinum compounds for colorectal cancer after cisplatin and carboplatin , and so far it has been the only envelope platinum drug which has a significant activity. The Principle is by producing alkylation conjugate to act on DNA, to form crosslinks within the chain and between the chain which inhibit DNA synthesis and replication.at the same time, it can inhibit the hyperplasia of ovarian cancer and melanoma cell lines. August 2002, the US Food and Drug Administration (FDA) approved the Sanofi Saint raborg company's anticancer drug oxaliplatin (, Eloxatin) for the second-line treatment of metastatic colon cancer. January 2004, the US Food and Drug Administration (FDA) formally approved the injection of oxaliplatin (Eloxatin) and 5-fluorouracil (5FU) and leucovorin (LV) Joint (FOLFOX program) for the first-line treatment of advanced colorectal cancer. The domestic market is currently dominated by Sanofi - Aventis (Eloxatin); Jiangsu Hengrui Medicine Co., Ltd. (Oxaliplatin); Jiangsu Nanjing Pharmaceutical (Austrian platinum) three manufacturers monopoly, which occupy more than 85% of the domestic market share . |
Adverse reactions and side effect |
1, the hematopoietic system: oxaliplatin has some hematologic toxicity. When administered alone,it can cause the following adverse reactions: anemia, leukopenia, neutropenia, thrombocytopenia, sometimes up to grade 3 or 4. When in combination with 5-fluorouracil , neutropenia and thrombocytopenia diseases’ hematological toxicity increases . 2, the digestive system:When administered alone, it can cause nausea, vomiting, diarrhea. These symptoms sometimes are very serious. When in combination with 5-fluorouracil, these side effects are increased significantly. It is Recommended to give preventive and / or therapeutic anti-emetic medication . 3,the nervous system: peripheral neuritis, characterized by peripheral sensory neuropathy. Sometimes there are accompanied around the mouth, upper respiratory tract and upper digestive tract spasms and sensory disorders. The above information is edited by the Chemicalbook of Tian Ye. |
Chemical Propertie | Triangular flaky colorless crystals. The water solubility is 7.9mg / ml. |
For the treatment of colorectal cancer. | |
production metho | 5g of trans-cyclohexanediamine and 18g K2 (PtCl4) aqueous solution react at room temperature for 12h, to give 12g intermediate product (I). 6: 8g of silver nitrate is added to 3g Compound (I) aqueous solution , the mixture is stirred for 2 ~ 3h under the dark, then add 4.8g oxalic acid dipotassium salt, react for 8h at room temperature , oxaliplatin is obtained . |
Chemical Properties | White Crystalline Solid |
Usage | Third generation platinum complex. An antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA. Antineoplastic. |
Usage | vasodilator |
Usage | A antitumor agent with activity against colorectal cancer. Cytotoxicity follows the formation of adducts with DNA |
Biological Activity | Antitumor agent that forms platinum-DNA adducts. Causes intra- and interstrand DNA crosslinks blocking DNA replication and transcription. Displays higher cytotoxicity and lower nephrotoxicity than analog cisplatin (cis-Diaminodichloroplatinum ) and shows antitumor activity in cell lines with acquired cisplatin resistance. |
CAS NO:83-56-7
CAS NO:582-17-2
CAS NO:532-02-5
CAS NO:83-56-7
CAS NO:81-04-9
CAS NO:106-91-2
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View